| Outcome Measures: |
Primary: Hepatic Steatosis, Hepatic steatosis measured by proton magnetic resonance spectroscopy (1H-MRS)., 3 and 6 months | Secondary: Metabolic Control as Measured by the A1c, 3 and 6 months|Change in Insulin Secretion, Derived from the hyperglycemic clamp (Plasma C-peptide change vs. pretreatment in first and second phase)., 3 and 6 months.|Intramyocellular (IMCL) by Magnetic Resonance Imaging and Spectroscopy (MRS)., Percent intramyocellular (IMCL) by magnetic resonance imaging and spectroscopy (MRS)., 3 and 6 months.|Plasma Lipid Concentration., Fasting plasma lipid concentration on day of admission at 3 and 6 months., 3 and 6 months.|Change in Anthropometric Measure (Body Weight)., Change in anthropometric measure (body weight) done on day of admission at 3 and 6 months., 3 and 6 months.|Number of Hypoglycemic Events, Defined as hypoglycemia \<40 mg/dl and/or requiring medical assistance during the trial., 3 and 6 months|Metabolic Control as Measured by the Fasting Plasma Glucose Concentration, 3 and 6 months|Metabolic Control as Measured by the Postprandial Plasma Glucose During the Day-long Plasma Glucose Profile., 3 and 6 months|Advanced Lipid Testing, Change in lipoprotein particle number was determined using NMR., 3 and 6 months|Change in Anthropometric Measure (Body Mass Index [BMI])., Change in anthropometric measure (body mass index \[BMI\]) done on day of admission at 3 and 6 months., 3 and 6 months.|Percent Change From Baseline in Vascular Inflammatory Markers, Inflammatory Markers include: Adiponectin, MMP-9, E-selectin, sICAM, and sVCAM, 3 and 6 months
|
